Recommendations about the urgent Recall of Valsartan In Response to the Potential Risk of Cancer
The South African Health Products Regulatory Authority (SAHPRA), in collaboration with other regulatory agencies are reviewing medicines containing the active substance valsartan, supplied by Zhejiang Huahai Pharmaceuticals, located in Linhai, China. This review was triggered because of the detection of an impurity, N-nitrosodimethylamine (NDMA) in…
